IMMUNE NETWORK

  • 제22권1호
  • /
  • Pages.12.1-12.13
  • /
  • 2022
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review

  • Sang Pyo Lee (Division of Pulmonology and Allergy, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine) ;
  • Yoo Seob Shin (Department of Allergy and Clinical Immunology, Ajou University School of Medicine) ;
  • Sung-Yoon Kang (Division of Pulmonology and Allergy, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine) ;
  • Tae-Bum Kim (Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Sang Min Lee (Division of Pulmonology and Allergy, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine)
  • 투고 : 2021.09.12
  • 심사 : 2022.01.10
  • 발행 : 2022.02.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Allergen-specific immunotherapy (AIT) is presumed to modulate the natural course of allergic disease by inducing immune tolerance. However, conventional AITs, such as subcutaneous immunotherapy and sublingual immunotherapy, require long treatment durations and often provoke local or systemic hypersensitivity reactions. Therefore, only <5% of allergy patients receive AIT as second-line therapy. Novel administration routes, such as intralymphatic, intradermal and epicutaneous immunotherapies, and synthetic recombinant allergen preparations have been evaluated to overcome these limitations. We will review the updated views of diverse AIT methods, and discuss the limitations and opportunities of the AITs for the treatment of allergic diseases in humans.

키워드

과제정보

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2015R1D1A1A02061943) and Ministry of Science, ICT and Future Planning (NRF-2019M3E5D3073365).

참고문헌

  1. Noon L, Freeman J. Prophylactic inoculation against hay fever. Lancet 1911;1:1572-1573. https://doi.org/10.1016/S0140-6736(00)78276-6
  2. Hoffmann HJ, Valovirta E, Pfaar O, Moingeon P, Schmid JM, Skaarup SH, Cardell LO, Simonsen K, Larche M, Durham SR, et al. Novel approaches and perspectives in allergen immunotherapy. Allergy 2017;72:1022-1034. https://doi.org/10.1111/all.13135
  3. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;111:437-448. https://doi.org/10.1067/mai.2003.129
  4. Kim ST, Park SH, Lee SM, Lee SP. Allergen-specific intralymphatic immunotherapy in human and animal studies. Asia Pac Allergy 2017;7:131-137. https://doi.org/10.5415/apallergy.2017.7.3.131
  5. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol 2016;137:339-349.e10. https://doi.org/10.1016/j.jaci.2015.12.1298
  6. Senti G, Kundig TM. Novel delivery routes for allergy immunotherapy: intralymphatic, epicutaneous, and intradermal. Immunol Allergy Clin North Am 2016;36:25-37. https://doi.org/10.1016/j.iac.2015.08.006
  7. Kersey TW, Van Eyk J, Lannin DR, Chua AN, Tafra L. Comparison of intradermal and subcutaneous injections in lymphatic mapping. J Surg Res 2001;96:255-259. https://doi.org/10.1006/jsre.2000.6075
  8. O'Mahony S, Solanki CK, Barber RW, Mortimer PS, Purushotham AD, Peters AM. Imaging of lymphatic vessels in breast cancer-related lymphedema: intradermal versus subcutaneous injection of 99mTc-immunoglobulin. AJR Am J Roentgenol 2006;186:1349-1355. https://doi.org/10.2214/AJR.04.1341
  9. Rotiroti G, Shamji M, Durham SR, Till SJ. Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol 2012;130:918-924.e1. https://doi.org/10.1016/j.jaci.2012.06.052
  10. Scheurer S, Toda M. Epicutaneous immunotherapy. Allergol Immunopathol (Madr) 2017;45 Suppl 1:25-29. https://doi.org/10.1016/j.aller.2017.09.007
  11. Senti G, Graf N, Haug S, Ruedi N, von Moos S, Sonderegger T, Johansen P, Kundig TM. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009;124:997-1002. https://doi.org/10.1016/j.jaci.2009.07.019
  12. Dickel H, Goulioumis A, Gambichler T, Fluhr JW, Kamphowe J, Altmeyer P, Kuss O. Standardized tape stripping: a practical and reproducible protocol to uniformly reduce the stratum corneum. Skin Pharmacol Physiol 2010;23:259-265. https://doi.org/10.1159/000314700
  13. Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol 1994;30:535-546. https://doi.org/10.1016/S0190-9622(94)70059-1
  14. Dickel H, Gambichler T, Kamphowe J, Altmeyer P, Skrygan M. Standardized tape stripping prior to patch testing induces upregulation of Hsp90, Hsp70, IL-33, TNF-α and IL-8/CXCL8 mRNA: new insights into the involvement of 'alarmins'. Contact Dermat 2010;63:215-222. https://doi.org/10.1111/j.1600-0536.2010.01769.x
  15. Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol 2011;352:71-84. https://doi.org/10.1007/82_2011_133
  16. Martinez-Gomez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kundig TM. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 2009;150:59-65. https://doi.org/10.1159/000210381
  17. Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, Steiner M, Hothorn LA, Gronlund H, Tivig C, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012;129:1290-1296. https://doi.org/10.1016/j.jaci.2012.02.026
  18. Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol 2013;131:412-420. https://doi.org/10.1016/j.jaci.2012.10.056
  19. Hylander T, Larsson O, Petersson-Westin U, Eriksson M, Kumlien Georen S, Winqvist O, Cardell LO. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res 2016;17:10.
  20. Hellkvist L, Hjalmarsson E, Kumlien Georen S, Karlsson A, Lundkvist K, Winqvist O, Westin U, Cardell LO. Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2018;142:1338-1341.e9. https://doi.org/10.1016/j.jaci.2018.05.030
  21. Freiberger SN, Zehnder M, Gafvelin G, Gronlund H, Kundig TM, Johansen P. IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human. Allergy 2016;71:1366-1370. https://doi.org/10.1111/all.12946
  22. Ahlbeck L, Ahlberg E, Nystrom U, Bjorkander J, Jenmalm MC. Intralymphatic allergen immunotherapy against pollen allergy: a 3-year open follow-up study of 10 patients. Ann Allergy Asthma Immunol 2018;121:626-627. https://doi.org/10.1016/j.anai.2018.07.010
  23. Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol 2013;132:1248-1252.e5. https://doi.org/10.1016/j.jaci.2013.07.033
  24. Schmid JM, Nezam H, Madsen HH, Schmitz A, Hoffmann HJ. Intralymphatic immunotherapy induces allergen specific plasmablasts and increases tolerance to skin prick testing in a pilot study. Clin Transl Allergy 2016;6:19.
  25. Lee SP, Choi SJ, Joe E, Lee SM, Lee MW, Shim JW, Kim YJ, Kyung SY, Park JW, Jeong SH, et al. A pilot study of intralymphatic immunotherapy for house dust mite, cat, and dog allergies. Allergy Asthma Immunol Res 2017;9:272-277. https://doi.org/10.4168/aair.2017.9.3.272
  26. Skaarup SH, Schmid JM, Skjold T, Graumann O, Hoffmann HJ. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial. J Allergy Clin Immunol 2021;147:1011-1019. https://doi.org/10.1016/j.jaci.2020.07.002
  27. Weinfeld D, Westin U, Hellkvist L, Mellqvist UH, Jacobsson I, Cardell LO. A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy. Allergy Asthma Clin Immunol 2020;16:31.
  28. Konradsen JR, Grundstrom J, Hellkvist L, Tran TA, Andersson N, Gafvelin G, Kiewiet MB, Hamsten C, Tang J, Parkin RV, et al. Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma: a randomized trial. J Allergy Clin Immunol 2020;145:1005-1007.e7. https://doi.org/10.1016/j.jaci.2019.11.017
  29. Kang SY, Jung JH, Lee SM, Lee SP. Intralymphatic allergen-specific immunotherapy. Allergy Asthma Respir Dis 2020;8:53-65. https://doi.org/10.4168/aard.2020.8.2.53
  30. Slovick A, Douiri A, Muir R, Guerra A, Tsioulos K, Hay E, Lam EP, Kelly J, Peacock JL, Ying S, et al. Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms. J Allergy Clin Immunol 2017;139:1830-1839.e13. https://doi.org/10.1016/j.jaci.2016.09.024
  31. Sola Martinez FJ, Barranco Jimenez RM, Martin Garcia C, Senent Sanchez C, Blanco Guerra C, Fernandez-Rivas M, Vega Castro A, Davila Gonzalez I, Carbonell Martinez A, Panizo Bravo C, et al. Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2020;50:1352-1361. https://doi.org/10.1111/cea.13740
  32. Senti G, von Moos S, Tay F, Graf N, Johansen P, Kundig TM. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy 2015;70:707-710. https://doi.org/10.1111/all.12600
  33. Senti G, von Moos S, Tay F, Graf N, Sonderegger T, Johansen P, Kundig TM. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012;129:128-135. https://doi.org/10.1016/j.jaci.2011.08.036
  34. von Moos S, Johansen P, Tay F, Graf N, Kundig TM, Senti G. Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy. J Allergy Clin Immunol 2014;134:965-7.e4. https://doi.org/10.1016/j.jaci.2014.07.037
  35. Agostinis F, Forti S, Di Berardino F. Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis. Allergy 2010;65:410-411. https://doi.org/10.1111/j.1398-9995.2009.02189.x
  36. Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H, Benhamou PH. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 2010;125:1165-1167. https://doi.org/10.1016/j.jaci.2010.02.029
  37. Jones SM, Agbotounou WK, Fleischer DM, Burks AW, Pesek RD, Harris MW, Martin L, Thebault C, Ruban C, Benhamou PH. Safety of epicutaneous immunotherapy for the treatment of peanut allergy: a phase 1 study using the Viaskin patch. J Allergy Clin Immunol 2016;137:1258-1261.e10. https://doi.org/10.1016/j.jaci.2016.01.008
  38. Jones SM, Sicherer SH, Burks AW, Leung DY, Lindblad RW, Dawson P, Henning AK, Berin MC, Chiang D, Vickery BP, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol 2017;139:1242-1252.e9. https://doi.org/10.1016/j.jaci.2016.08.017
  39. Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, Cheema AS, Leonard SA, Pongracic JA, Sauvage-Delebarre C, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA 2017;318:1798-1809. https://doi.org/10.1001/jama.2017.16591
  40. Fleischer DM, Greenhawt M, Sussman G, Begin P, Nowak-Wegrzyn A, Petroni D, Beyer K, Brown-Whitehorn T, Hebert J, Hourihane JO, et al. Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial. JAMA 2019;321:946-955. https://doi.org/10.1001/jama.2019.1113
  41. Spergel JM, Elci OU, Muir AB, Liacouras CA, Wilkins BJ, Burke D, Lewis MO, Brown-Whitehorn T, Cianferoni A. Efficacy of epicutaneous immunotherapy in children with milk-induced eosinophilic esophagitis. Clin Gastroenterol Hepatol 2020;18:328-336.e7. https://doi.org/10.1016/j.cgh.2019.05.014
  42. Xiong L, Lin J, Luo Y, Chen W, Dai J. The efficacy and safety of epicutaneous immunotherapy for allergic diseases: a systematic review and meta-analysis. Int Arch Allergy Immunol 2020;181:170-182. https://doi.org/10.1159/000504366
  43. Park HJ, Kim SH, Shin YS, Park CH, Cho ES, Choi SJ, Park SH, Jung JH, Kang IG, Lee MS, et al. Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial. Respir Res 2021;22:170.
  44. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, Simard JJ, Wuthrich B, Crameri R, Graf N, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008;105:17908-17912. https://doi.org/10.1073/pnas.0803725105
  45. Patterson AM, Bonny AE, Shiels WE 2nd, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol 2016;116:168-170. https://doi.org/10.1016/j.anai.2015.11.010
  46. Lee SP, Jung JH, Lee SM, Joe E, Kang IG, Kim ST, Lee MW, Park SH, Choi SJ. Intralymphatic immunotherapy alleviates allergic symptoms during allergen exposure in daily life. Allergy Asthma Immunol Res 2018;10:180-181. https://doi.org/10.4168/aair.2018.10.2.180
  47. Terada T, Omura S, Kikuoka Y, Suzuki M, Inaka Y, Inui T, Matsuda M, Nabe T, Kawata R. Sustained effects of intralymphatic pollen-specific immunotherapy on Japanese cedar pollinosis. Rhinology 2020;58:241-247. https://doi.org/10.4193/Rhin19.301
  48. Thompson CP, Silvers S, Shapiro MA. Intralymphatic immunotherapy for mountain cedar pollinosis: A randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 2020;125:311-318.e2. https://doi.org/10.1016/j.anai.2020.04.030
  49. Wang K, Zheng R, Chen Y, Yu Q, Zhong H, Xiao P, Wang Y, Tang J. Clinical efficacy and safety of cervical intralymphatic immunotherapy for house dust mite allergic rhinitis: a pilot study. Am J Otolaryngol 2019;40:102280.
  50. Werner MT, Bosso JV. Intralymphatic immunotherapy for allergic rhinitis: a systematic review and meta-analysis. Allergy Asthma Proc 2021;42:283-292. https://doi.org/10.2500/aap.2021.42.210028
  51. Hoang MP, Seresirikachorn K, Chitsuthipakorn W, Snidvongs K. Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Rhinology 2021;59:236-244. https://doi.org/10.4193/Rhin20.572
  52. Kundig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol 2014;133:930-931. https://doi.org/10.1016/j.jaci.2013.11.036
  53. Henmar H, Lund G, Lund L, Petersen A, Wurtzen PA. Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin Exp Immunol 2008;153:316-323. https://doi.org/10.1111/j.1365-2249.2008.03710.x
  54. Skaarup SH, Graumann O, Schmid J, Bjerrum AS, Skjold T, Hoffmann HJ. The number of successful injections associates with improved clinical effect in intralymphatic immunotherapy. Allergy 2021;76:1859-1861. https://doi.org/10.1111/all.14642
  55. Aini NR, Mohd Noor N, Md Daud MK, Wise SK, Abdullah B. Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis: a systematic review and meta-analysis. Clin Transl Allergy 2021;11:e12055.
  56. Norman PS, Winkenwerder WL, D'Lugoff BC, Tignall J. Controlled evaluations of repository therapy in ragweed hay fever. J Allergy 1967;39:82-92. https://doi.org/10.1016/0021-8707(67)90114-1
  57. Norman PS, Winkenwerder WL, Lichtenstein LM. Trials of alum-precipitated pollen extracts in the treatment of hay fever. J Allergy Clin Immunol 1972;50:31-44. https://doi.org/10.1016/0091-6749(72)90077-2
  58. Casanovas M, Sastre J, Fernandez-Nieto M, Lluch M, Carnes J, Fernandez-Caldas E. Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense. Clin Exp Allergy 2005;35:1377-1383. https://doi.org/10.1111/j.1365-2222.2005.02343.x
  59. Pfaar O, Robinson DS, Sager A, Emuzyte R. Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy 2010;65:1614-1621. https://doi.org/10.1111/j.1398-9995.2010.02413.x
  60. DuBuske LM, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W, Holdich T, von Weikersthal-Drachenberg KJ. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011;32:239-247. https://doi.org/10.2500/aap.2011.32.3453
  61. Klimek L, Kundig T, Kramer MF, Guethoff S, Jensen-Jarolim E, Schmidt-Weber CB, Palomares O, Mohsen MO, Jakob T, Bachmann M. Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases. Allergo J Int 2018;27:245-255. https://doi.org/10.1007/s40629-018-0074-y
  62. Pechsrichuang P, Namwongnao S, Jacquet A. Bioengineering of virus-like particles for the prevention or treatment of allergic diseases. Allergy Asthma Immunol Res 2021;13:23-41. https://doi.org/10.4168/aair.2021.13.1.23
  63. Kim J, Oh J, Kang CS, Choi YS. Virus-like Particle (VLP) mediated antigen delivery as a sensitization tool of experimental allergy mouse models. Immune Netw 2020;20:e35.
  64. Nelson HS. Chapter 85. Injection immunotherapy for inhalant allergens. In: Middleton's Allergy Principles and Practice, 9th ed. Burks AW, Holgate ST, O'Hehir RE, Broide DH, Bacharier LB, Khurana Hershey GK, Peebles RS, eds. New York, NY; Elsevier; 2020. p.1401-1419.
  65. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608-613. https://doi.org/10.1016/j.jaci.2005.06.004
  66. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, Purohit A, Arvidsson M, Kavina A, Schroeder JW, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951-960. https://doi.org/10.1016/j.jaci.2008.09.017
  67. Klimek L, Bachert C, Lukat KF, Pfaar O, Meyer H, Narkus A. Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial. Clin Transl Allergy 2015;5:28.
  68. Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z, Wood RA, Eggleston PA, Hafner KB, Rao P, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996;154:1623-1628. https://doi.org/10.1164/ajrccm.154.6.8970345
  69. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999;93:222-231. https://doi.org/10.1006/clim.1999.4795
  70. Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, Buhot C, Verhoef A, Maillere B, Kay AB, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011;127:89-97. https://doi.org/10.1016/j.jaci.2010.11.029
  71. Couroux P, Patel D, Armstrong K, Larche M, Hafner RP. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy 2015;45:974-981. https://doi.org/10.1111/cea.12488
  72. Spertini F, DellaCorte G, Kettner A, de Blay F, Jacobsen L, Jutel M, Worm M, Charlon V, Reymond C. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. J Allergy Clin Immunol 2016;138:162-168. https://doi.org/10.1016/j.jaci.2016.02.044
  73. Broide D, Schwarze J, Tighe H, Gifford T, Nguyen MD, Malek S, Van Uden J, Martin-Orozco E, Gelfand EW, Raz E. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998;161:7054-7062. https://doi.org/10.4049/jimmunol.161.12.7054
  74. Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, Kagey-Sobotka A, Creticos PS, Lichtenstein LM, Spiegelberg HL, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000;106:124-134. https://doi.org/10.1067/mai.2000.107927
  75. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445-1455. https://doi.org/10.1056/NEJMoa052916
  76. Klimek L, Willers J, Hammann-Haenni A, Pfaar O, Stocker H, Mueller P, Renner WA, Bachmann MF. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 2011;41:1305-1312. https://doi.org/10.1111/j.1365-2222.2011.03783.x
  77. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Muller P, Pfister T, Maurer P, Bachmann MF, Graf N, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009;39:562-570. https://doi.org/10.1111/j.1365-2222.2008.03191.x
  78. Sirvent S, Soria I, Cirauqui C, Cases B, Manzano AI, Diez-Rivero CM, Reche PA, Lopez-Relano J, Martinez-Naves E, Canada FJ, et al. Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1. J Allergy Clin Immunol 2016;138:558-567.e11. https://doi.org/10.1016/j.jaci.2016.02.029
  79. Saxon A, Kepley C, Zhang K. "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling. J Allergy Clin Immunol 2008;121:320-325. https://doi.org/10.1016/j.jaci.2007.10.017